Role of iNKT Cells in Autoimmunity and Atherosclerosis

iNKT 细胞在自身免疫和动脉粥样硬化中的作用

基本信息

  • 批准号:
    7900350
  • 负责人:
  • 金额:
    $ 38.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-09-25 至 2012-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Atherosclerosis is a chronic inflammatory disease associated with the activation of both innate and adaptive immune responses. Minority populations and young women with systemic lupus erythematosus are particularly prone to the development of atherosclerosis. Recently, a unique group of T lymphocytes, called invariant natural killer T (iNKT) cells, have been implicated in atherogenesis and lupus. This Project will test the hypothesis that iNKT cells are chronically activated during hyperlipidemia and that this conversion is uniquely involved in regulating and/or modulating an inflammatory response that exacerbates atherosclerosis and dysregulates immunity. This hypothesis is based on key preliminary studies demonstrating that (a) iNKT cell numbers and functions are altered in spontaneously hyperlipidemic apoE-deficient (apoE-/-) mice; (b) iNKT cells of apoE-/- mice express phenotypic markers distinct from wild type iNKT cells, suggesting activation; (c) absence of iNKT cells in apoE-/- mice reduces atherosclerosis but aggravates lupus; and (d) specific activation of iNKT cells in vivo is proatherogenic but protects against lupus. Based on these findings, the overall objective of this Project is to characterize the immunoregulatory mechanism(s) by which iNKT cells promote lesion formation in the artery wall. Our specific aims are to: (1) investigate the effects of hyperlipidemia and atherosclerosis on iNKT cell numbers and functions in apoE-/- mice; (2) investigate the role of cytokine production by iNKT cells and subsequent immune activation in atherosclerosis and (3) determine the role of iNKT cells in lupus-accelerated atherosclerosis. Relevance to Public Health: Coronary heart disease associated with atherosclerosis is the primary cause of mortality in the United States. At extremely high risk for suffering a fatal cardiac event are young women with lupus. Lupus-accelerated atherosclerosis is independent of cholesterol levels and is thought to be largely associated with autoimmune dysregulation. iNKT cells represent some of the most potent immune regulators. Therefore, understanding their significance in lupus and atherosclerosis will provide valuable insights for the future generation of immunotherapy to treat both lupus and heart disease.
描述(由申请人提供):动脉粥样硬化是一种与先天性和适应性免疫应答激活相关的慢性炎性疾病。患有系统性红斑狼疮的少数人群和年轻女性特别容易发生动脉粥样硬化。最近,一组独特的T淋巴细胞,称为不变的自然杀伤T(iNKT)细胞,已涉及动脉粥样硬化和狼疮。该项目将检验iNKT细胞在高脂血症期间被慢性激活的假设,并且这种转换独特地参与调节和/或调节加剧动脉粥样硬化和免疫失调的炎症反应。该假设基于关键的初步研究,该研究表明:(a)iNKT细胞数量和功能在自发性高脂血症apoE-缺陷(apoE-/-)小鼠中改变;(B)apoE-/-小鼠的iNKT细胞表达与野生型iNKT细胞不同的表型标志物,表明激活;(c)apoE-/-小鼠中iNKT细胞的缺失减少动脉粥样硬化但加重狼疮;和(d)iNKT细胞在体内的特异性活化是促动脉粥样硬化的,但保护免于狼疮。基于这些发现,本项目的总体目标是表征iNKT细胞促进动脉壁病变形成的免疫调节机制。我们的具体目标是:(1)研究高脂血症和动脉粥样硬化对apoE-/-小鼠iNKT细胞数量和功能的影响;(2)研究iNKT细胞产生细胞因子和随后的免疫激活在动脉粥样硬化中的作用;(3)确定iNKT细胞在狼疮加速的动脉粥样硬化中的作用。 与公共卫生的相关性:在美国,与动脉粥样硬化相关的冠心病是死亡的主要原因。患有狼疮的年轻女性患致命性心脏病的风险极高。狼疮加速的动脉粥样硬化与胆固醇水平无关,被认为与自身免疫失调密切相关。iNKT细胞代表了一些最有效的免疫调节剂。因此,了解它们在狼疮和动脉粥样硬化中的意义将为未来治疗狼疮和心脏病的免疫疗法提供有价值的见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

AMY S MAJOR其他文献

AMY S MAJOR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('AMY S MAJOR', 18)}}的其他基金

Investigating mechanisms of oxidized phospholipid-mediated dysregulation of regulatory T cells in atherosclerosis
研究动脉粥样硬化中氧化磷脂介导的调节性 T 细胞失调的机制
  • 批准号:
    10648711
  • 财政年份:
    2023
  • 资助金额:
    $ 38.38万
  • 项目类别:
Fc Receptors in Atherosclerosis: Linking Innate and Adaptive Immunity.
Fc§§ 动脉粥样硬化受体:连接先天免疫和适应性免疫。
  • 批准号:
    10450688
  • 财政年份:
    2021
  • 资助金额:
    $ 38.38万
  • 项目类别:
Fc Receptors in Atherosclerosis: Linking Innate and Adaptive Immunity.
Fc§§ 动脉粥样硬化受体:连接先天免疫和适应性免疫。
  • 批准号:
    10664909
  • 财政年份:
    2021
  • 资助金额:
    $ 38.38万
  • 项目类别:
Fc Receptors in Atherosclerosis: Linking Innate and Adaptive Immunity.
Fc§§ 动脉粥样硬化受体:连接先天免疫和适应性免疫。
  • 批准号:
    10259917
  • 财政年份:
    2021
  • 资助金额:
    $ 38.38万
  • 项目类别:
Targeting Tfh Cell Metabolic Regulation in SLE and SLE-Associated Atherosclerosis
针对 SLE 和 SLE 相关动脉粥样硬化的 Tfh 细胞代谢调节
  • 批准号:
    10029497
  • 财政年份:
    2020
  • 资助金额:
    $ 38.38万
  • 项目类别:
Targeting Tfh Cell Metabolic Regulation in SLE and SLE-Associated Atherosclerosis
针对 SLE 和 SLE 相关动脉粥样硬化的 Tfh 细胞代谢调节
  • 批准号:
    10609478
  • 财政年份:
    2020
  • 资助金额:
    $ 38.38万
  • 项目类别:
Targeting Tfh Cell Metabolic Regulation in SLE and SLE-Associated Atherosclerosis
针对 SLE 和 SLE 相关动脉粥样硬化的 Tfh 细胞代谢调节
  • 批准号:
    10380090
  • 财政年份:
    2020
  • 资助金额:
    $ 38.38万
  • 项目类别:
Immunological Mechanisms of Disease Training Program
疾病免疫机制培训计划
  • 批准号:
    10640277
  • 财政年份:
    2019
  • 资助金额:
    $ 38.38万
  • 项目类别:
Immunological Mechanisms of Disease Training Program
疾病免疫机制培训计划
  • 批准号:
    9791561
  • 财政年份:
    2019
  • 资助金额:
    $ 38.38万
  • 项目类别:
Immunological Mechanisms of Disease Training Program
疾病免疫机制培训计划
  • 批准号:
    10413896
  • 财政年份:
    2019
  • 资助金额:
    $ 38.38万
  • 项目类别:

相似海外基金

Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
  • 批准号:
    10751133
  • 财政年份:
    2023
  • 资助金额:
    $ 38.38万
  • 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
  • 批准号:
    10696138
  • 财政年份:
    2022
  • 资助金额:
    $ 38.38万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10663066
  • 财政年份:
    2022
  • 资助金额:
    $ 38.38万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10537159
  • 财政年份:
    2022
  • 资助金额:
    $ 38.38万
  • 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
  • 批准号:
    21K08723
  • 财政年份:
    2021
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10156950
  • 财政年份:
    2021
  • 资助金额:
    $ 38.38万
  • 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
  • 批准号:
    10631854
  • 财政年份:
    2021
  • 资助金额:
    $ 38.38万
  • 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
  • 批准号:
    10153927
  • 财政年份:
    2021
  • 资助金额:
    $ 38.38万
  • 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10331830
  • 财政年份:
    2021
  • 资助金额:
    $ 38.38万
  • 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
  • 批准号:
    20K16294
  • 财政年份:
    2020
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了